Welcome to our dedicated page for Klotho Neurosciences SEC filings (Ticker: KLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Klotho Neurosciences, Inc. (NASDAQ: KLTO), a Delaware-incorporated biogenetics and biotechnology company. Through these filings, investors can review how Klotho describes its Klotho gene-based cell and gene therapy programs, its financing activities, and its status as a Nasdaq-listed emerging growth company and smaller reporting company.
Key documents include registration statements such as the Form S-1, which for Klotho details the resale of common stock issuable upon conversion of its Series C Convertible Preferred Stock and shares held by an existing stockholder. That filing explains the terms of the preferred stock, the planned resale by selling stockholders, and notes that the company will not receive proceeds from those resales. It also provides information on risk factors, plan of distribution, and other disclosures that frame Klotho’s capital structure and financing approach.
Investors can also examine current reports on Form 8-K, where Klotho reports material events. For example, an 8-K describes an amendment to a subscription agreement affecting the term and maximum number of shares under that agreement, while another 8-K discloses a Nasdaq delinquency notification letter related to the minimum bid price requirement under Listing Rule 5550(a)(2). These filings outline the timeline provided by Nasdaq for regaining compliance and the potential consequence of delisting if compliance is not restored.
Beyond these examples, the KLTO filings set out the company’s status as an emerging growth company, its listing of common stock and warrants on the Nasdaq Capital Market, and its use of preferred stock and other securities in financing. On Stock Titan, SEC documents for KLTO are updated as they are made available through EDGAR, and AI-powered tools can help summarize lengthy registration statements and current reports so readers can more quickly understand the core terms, risks, and corporate actions described in Klotho Neurosciences’ regulatory disclosures.
Joseph Sinkule, who serves as Chief Executive Officer and a Director of Klotho Neurosciences, acquired 400,000 shares of the company's common stock on 09/25/2025. The filing states these shares were returned to him after he canceled a portion of a previously-reported non-recourse loan that had used the shares as collateral. After this transaction, Sinkule beneficially owns 4,846,700 shares, which the filing clarifies includes 1,000,000 shares issuable upon exercise of incentive options. The Form 4 is signed and dated 09/29/2025 and reports the change as a non-derivative acquisition by an executive who is also a director.
Klotho Neurosciences, Inc. entered into an Amendment to its June 13, 2024 Subscription Agreement with several Meteora investment entities. The Amendment extends the term of the Subscription Agreement until September 19, 2025 and sets the maximum number of shares that can be issued under the agreement at 6,755,000. The company notes that this brief description is qualified in its entirety by the full Amendment, which is filed as an exhibit.
Klotho Neurosciences, Inc. reported that it received a delinquency notice from Nasdaq because its common stock failed to maintain the required minimum bid price of $1 per share for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, until March 18, 2026, to regain compliance by having its closing bid price at or above $1 per share for at least ten consecutive business days before that date. If it does not regain compliance within this period, its common stock will be subject to delisting from Nasdaq.